ArticleInternational journal of clinical and experimental pathology2017
CXCR4 enhances invasion and proliferation of bone marrow stem cells via PI3K/AKT/NF-κB signaling pathway.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- Engineering MSC Migration: Roles of Nanoparticles in Activating Migratory Pathways and Functions.International journal of molecular sciences · 2026Review
- STMN1 regulates the stemness of gastric cancer cells by binding to HN1L to activate the STAT3 signaling pathway.Discover oncology · 2025Article
- Mesenchymal stem cells as therapeutic vehicles for glioma.Cancer gene therapy · 2024Review
- Genome-wide association study to identify SNPs and candidate genes associated with body size traits in donkeys.Frontiers in genetics · 2023Article
- Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications.World journal of stem cells · 2022Review
- The roles of glycolysis in osteosarcoma.Frontiers in pharmacology · 2022Review
- Stromal cell-derived factor-1/Exendin-4 cotherapy facilitates the proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells in vitro and promotes periodontal bone regeneration in vivo.Cell proliferation · 2021Article
- Targeting MAD2 modulates stemness and tumorigenesis in human Gastric Cancer cell lines.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common type of cancer that develops in bone, specifically; it is an aggressive malignant neoplasm. The purpose of this study is using superparamagnetic iron oxide nanoparticles (SPION) labeled bone mesenchymal stem cells (MSCs) to migrate into cancerous parts, then using alternating magnetic field to produce the high temperature to kill cancer cells in vitro. In order to enhance the invasion ability of MSCs, we successfully overexpressed CXCR4 in MSCs, we found the invasion behavior of CXCR4 overexpressed MSCs and CXCR4 overexpressed SPION labeled MSCs was enhanced when compared with MSCs. In addition, the proliferation of CXCR4 overexpressed MSCs and CXCR4 overexpressed SPION labeled MSCs. Then, we found that CXCR4 was able to enhance invasion related genes expression, including MMP9, MMP2, MMP13, MMP7, MMP10, MMP8, and MMP1. Among these genes, MMP9 and MMP2 were associated with PI3K/AKT/NF-κB signaling. The expression of MMP9 and MMP2 was decreased when PI3K/AKT signaling inhibitor LY294002 and NF-κB inhibitor PDTC were used respectively. Moreover the migrated of CXCR4 overexpressed MSCs and CXCR4 overexpressed SPION labeled MSCs were significantly reduced after LY294002 and PDTC used. These results suggest that CXCR4 overexpressed SPION labeled MSCs can be more easier migrate into cancerous parts; it may provide a promising method to treat the osteosarcoma.
Indexed as
Identifiers
31966870PMC6965991W3009400934What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.